325 related articles for article (PubMed ID: 21890422)
41. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.
Chhajed PN; Baty F; Pless M; Somandin S; Tamm M; Brutsche MH
Chest; 2006 Dec; 130(6):1803-7. PubMed ID: 17167000
[TBL] [Abstract][Full Text] [Related]
42. Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Takiguchi Y; Seto T; Ichinose Y; Nogami N; Shinkai T; Okamoto H; Minato K; Seki N; Eguchi K; Kishi K; Nishikawa M; Watanabe K
J Thorac Oncol; 2011 Jan; 6(1):156-60. PubMed ID: 21107293
[TBL] [Abstract][Full Text] [Related]
43. Outcomes after adjuvant platinum-based chemotherapy in elderly NSCLC patients with T4 disease.
Sigel K; Mhango G; Cohen J; Halm EA; Mandeli J; Strauss G; Wisnivesky J
Ann Surg Oncol; 2013 Mar; 20(3):1013-9. PubMed ID: 23115004
[TBL] [Abstract][Full Text] [Related]
44. Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Popat S; Barbachano Y; Ashley S; Norton A; O'Brien M
Lung Cancer; 2008 Feb; 59(2):227-31. PubMed ID: 17920156
[TBL] [Abstract][Full Text] [Related]
45. Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Fujimoto N; Kiura K; Takigawa N; Fujiwara Y; Toyooka S; Umemura S; Tabata M; Ueoka H; Tanimoto M
Acta Med Okayama; 2010 Feb; 64(1):33-7. PubMed ID: 20200582
[TBL] [Abstract][Full Text] [Related]
46. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients.
Dediu M; Ion O; Ion R; Alexandru A; Median D; Gal C; Horvat T; Motas C; Motas N
J BUON; 2012; 17(2):317-22. PubMed ID: 22740212
[TBL] [Abstract][Full Text] [Related]
47. Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.
Gebbia V; Bellavia M; Banna GL; Russo P; Ferraù F; Tralongo P; Borsellino N
Clin Lung Cancer; 2013 Jul; 14(4):390-8. PubMed ID: 23313173
[TBL] [Abstract][Full Text] [Related]
48. Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
Goto Y; Sekine I; Yamada K; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
J Thorac Oncol; 2008 Apr; 3(4):412-6. PubMed ID: 18379361
[TBL] [Abstract][Full Text] [Related]
49. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer.
Kubota K; Sakai H; Yamamoto N; Kunitoh H; Nakagawa K; Takeda K; Ichinose Y; Saijo N; Ariyoshi Y; Fukuoka M
J Thorac Oncol; 2010 May; 5(5):702-6. PubMed ID: 20150827
[TBL] [Abstract][Full Text] [Related]
50. Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
Fan WC; Yu CJ; Tsai CM; Huang MS; Lai CL; Hsia TC; Tien YJ; Huang SF; Wu CH; Chou KT; Lee YC; Perng RP; Chen YM
J Thorac Oncol; 2011 Jan; 6(1):148-55. PubMed ID: 21107294
[TBL] [Abstract][Full Text] [Related]
51. Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients.
Lee DH; Han JY; Kim HT; Lee JS
Lung Cancer; 2006 Sep; 53(3):339-45. PubMed ID: 16824646
[TBL] [Abstract][Full Text] [Related]
52. A retrospective study of the novel combination of paclitaxel and S1 for pretreated advanced non-small cell lung cancer.
Aono N; Ito Y; Nishino K; Uchida J; Kumagai T; Akazawa Y; Okuyama T; Yoshinami T; Imamura F
Chemotherapy; 2012; 58(6):454-60. PubMed ID: 23392470
[TBL] [Abstract][Full Text] [Related]
53. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy.
Sun JM; Park JO; Won YW; Kim JH; Yun J; Lee J; Park YH; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2010 Apr; 5(4):540-5. PubMed ID: 20195170
[TBL] [Abstract][Full Text] [Related]
54. Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib.
Wataya H; Okamoto T; Maruyama R; Seto T; Yamazaki K; Tagawa T; Fukuyama S; Osoegawa A; Ikeda J; Nishimura M; Yamanaka T; Ichinose Y
Lung Cancer; 2009 Jun; 64(3):341-5. PubMed ID: 18995926
[TBL] [Abstract][Full Text] [Related]
55. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
Kaneda H; Okamoto I; Hayashi H; Yoshioka H; Miyazaki M; Kudoh S; Kimura T; Sugiura T; Sawa T; Takeda K; Iwamoto Y; Satouchi M; Akita K; Saito H; Goto I; Shibata K; Fukuoka M; Nakagawa K;
J Thorac Oncol; 2010 Jan; 5(1):105-9. PubMed ID: 19884859
[TBL] [Abstract][Full Text] [Related]
56. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
57. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
[TBL] [Abstract][Full Text] [Related]
58. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
Wheatley-Price P; Le Maître A; Ding K; Leighl N; Hirsh V; Seymour L; Bezjak A; Shepherd FA;
J Thorac Oncol; 2010 May; 5(5):640-8. PubMed ID: 20354457
[TBL] [Abstract][Full Text] [Related]
59. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
Laurie SA; Goss GD; Shepherd FA; Reaume MN; Nicholas G; Philip L; Wang L; Schwock J; Hirsh V; Oza A; Tsao MS; Wright JJ; Leighl NB
Clin Lung Cancer; 2014 Jan; 15(1):52-7. PubMed ID: 24169259
[TBL] [Abstract][Full Text] [Related]
60. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Massarelli E; Andre F; Liu DD; Lee JJ; Wolf M; Fandi A; Ochs J; Le Chevalier T; Fossella F; Herbst RS
Lung Cancer; 2003 Jan; 39(1):55-61. PubMed ID: 12499095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
